原发灶不明肿瘤.ppt

* Overall survival (n = 60). The median survival time was 12.6 months; the 1- and 2-year survival rates were 51% and 27%, respectively. Waterfall plot showing the best response of all patients with measurable disease (n = 46). Overall survival (n = 60). The median survival time was 12.6 months; the 1- and 2-year survival rates were 51% and 27%, respectively. Grade 3 or 4 treatment-related toxicity during paclitaxel–carboplatin–bevacizumab–erlotinib treatment (60 patients, 222 courses)? Progression-free survival (PFS; N = 51). Overall survival (N = 51). * * 44699, 4.5,20%,4.7% * *In an analysis of 12 post-mortem cohort studies from 1944 to 2000,9 the primary tumor was identified in 644 (73%) of 884 patients. * lung (27%) pancreatic (24%)iver or bile duct (8%) kidney or adrenals (8%)colon or rectum (7%) genital system (7%) stomach (6%)  * 44699, 4.5,20%,4.7% * 689 patients, 358 (52%) individuals had N2 or N3 disease, 83% of patients had ductal carcinoma, with oestrogen receptors present in 43%. 321 (72%) of 446 patients undergoing mastectomy * 1、the most common clinical presentation 2. jugulodigastric or upper nodes are most frequently implicated (30–50% of patients). 3. has a diagnostic accuracy of almost 95% and is widely used 4. detect the primary tumour of squamous-cell carcinoma in 22% of patients * typical,well differentiated carcinoids or islet-cell tumours of unknown primaries 2. clinically similar to small-cell lung cancer 3. present at many sites and have an aggressive course 4. Such as Chromogranin and synaptophysin * 1.Histological examination 2. independent prognostic factors; Men、blastic bone metastases、high PSA(病理标本前列腺特异抗原必须要做），visceral metastases a colon-cancer profile for CK20 and homeobox protein CDX2、negative for CK7 favourable prognosis 3. 2500 patients, male sex, performance status of more than 1, high comorbidity score,age older than 64 years, history of smoking (more than10 pack-years), weight loss, and laboratory parameterssuch as lymphopen